Brief: Larimar Therapeutics Announces Dosing Of First Patient In Long-Term Open Label Extension Study For Nomlabofusp

Larimar Therapeutics

11/03/2024 20:16

March 11 (Reuters) - Larimar Therapeutics Inc  LRMR.O :
    * LARIMAR THERAPEUTICS ANNOUNCES THE DOSING OF THE FIRST
PATIENT
IN LONG-TERM OPEN LABEL EXTENSION STUDY FOR NOMLABOFUSP IN
PATIENTS WITH FRIEDREICH’S ATAXIA
    * LARIMAR THERAPEUTICS INC - STUDY WILL INFORM ON LONG-TERM
SAFETY
PROFILE AND TISSUE FRATAXIN LEVELS
    * LARIMAR THERAPEUTICS INC - OLE INITIATED WITH 25 MG DAILY
SUBCUTANEOUS INJECTIONS OF NOMLABOFUSP
    * LARIMAR - FRATAXIN DATA & SAFETY DATA FROM OLE STUDY
INTENDED TO
HELP SUPPORT POTENTIAL BLA SUBMISSION FOR ACCELERATED APPROVAL
TARGETED FOR H2 2025
    * LARIMAR THERAPEUTICS INC - INITIAL DATA EXPECTED IN Q4
2024

Source text for Eikon:  ID:nGNX5CyHLP 
Further company coverage:  LRMR.O 

 ((Reuters.Briefs@thomsonreuters.com;))